Medical Insights from Industry

RSS

"Insights from Industry" is a dynamic series of interviews at the cutting edge of the medical industry. Every interviewee is a leader in their particular field and is handpicked to give an informative and accessible insight into their chosen field. These interviews are guaranteed to keep you in the know in a rapidly changing industry.

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

For my MD thesis I modified and evaluated an immunological assay that detected the cell death products “nucleosomes” as a new blood-based cancer biomarker. As cell death processes are enhanced or suppressed during different stages of tumor development, it was assumed that they may enable stage-dependent detection of cancer disease.

12 Dec 2013

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

The need for biosimulation is primarily to do with the very high attrition rate in drug development and especially in the development of drugs for the central nervous system.

10 Dec 2013

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Untreated, the mortality probably exceeds 70%. Flesh eating is a description of Toxic Inflammatory Cellulitis which usually starts by bacterial subcutaneous infection followed by freezing in phase II healing which is inflammatory.

9 Dec 2013

Type 2 diabetes management: an interview with Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim

The rate of Type 2 Diabetes is rapidly increasing, particularly in Asian countries which make up more than 60 percent of the world’s diabetes population. So it’s really important physicians feel confident managing this chronic condition in their daily clinical practice.

5 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Dye reduction in diagnostic heart procedures: an interview with Mike McCormick, CEO Osprey Medical

Iodine based contrast media (dye) is radiopaque and is commonly used for diagnostic and interventional heart procedures. It allows physicians to see real time images of the heart vessels and treat any blockages.

3 Dec 2013

Diagnosing colonic polyps: an interview with Dr. Haili Wang, Metabolomic Technologies Inc. (MTI)

Colorectal cancer is a leading cause of death in North America, but it is preventable if found at the colonic polyp stage. Currently, only 39% of colorectal cancer cases in the US are diagnosed at an early and treatable stage.

28 Nov 2013

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.

27 Nov 2013

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

What we are trying to do is take a cancer model like the PDX model (patient-derived tumor xenograft), which is a human-derived cancer growing in an in vivo model and apply radiation to that model.

From Xstrahl 20 Nov 2013

Medical image exchange: an interview with Willie Tillery, CEO of Accelarad

Accelarad’s team first recognized the need for the virtualization of radiology more than 10 years ago. Over the past six years, the industry has readily adopted cloud-based medical image exchanges, as evidenced by the thousands of physicians who share nearly half a billion images via Accelarad each year.

18 Nov 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Cancer can be treated by a number of different ways depending on the location, grade and stage of tumour. A patient's age, medical history and lifestyle will also be taken into consideration and a combination of treatments will also be adopted to provide maximum effect.

14 Nov 2013

Infection prevention: an interview with Dr. Robert Gorab, Chief Medical Officer, Hoag Orthopedic Institute

HOI has one of the lowest if not the lowest surgical readmission rate in the State of California. Our all-cause readmission rate is 3.3% and our joint replacement readmission was at 1.8% based on published CMS reports we received in September 2013.

12 Nov 2013

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

The prostate gland produces part of the seminal fluid that protects sperm. It is located in front of the rectum and under the bladder, and surrounds the urethra, the tube through which urine flows from the bladder to and out of the penis.

6 Nov 2013

Biomedical testing: an interview with Ed Moriarty, General Manager of the ElectroForce Systems Group of Bose Corporation

An interview with Ed Moriarty, discussing how Bose are involved in the development of advanced testing equipment for medical devices.

From TA Instruments 4 Nov 2013

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Crown serves pharmaceutical companies and biotech companies. We have two areas of focus: oncology and metabolic diseases. In the oncology space we focus on pre-clinical services. Essentially, we have all the tools to help our customers move from target discovery, target validation, to a clinical candidate.

31 Oct 2013

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Firstly, actinic keratosis (AK) is a common dermatological condition caused by cumulative exposure to the sun. Providing patients with effective treatment is very important, as AK can lead to forms of non-melanoma skin cancer (NMSC) if not diagnosed and treated early. In fact, two in three cases of squamous cell carcinoma (a common form of skin cancer), begin as AK.

29 Oct 2013

Pertussis incidence: an interview with Leonard Friedland, M.D., V.P. and Director of Scientific Affairs and Public Health for GSK Vaccines

Distinguishing pertussis (also known as whooping cough) from other respiratory illnesses is challenging in particular among adults because the signs and symptoms of pertussis overlap with those of other respiratory diseases.

24 Oct 2013

COPD treatments: an interview with Professor Price, University of Aberdeen

The first thing is that we can’t cure COPD. The problem we have with COPD is that the process itself is not treatable, certainly not once it gets to the extent that it’s advanced.

22 Oct 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

House dust mite allergy is a surprisingly prevalent problem. Something like 27% of the U.S. population and 20% of the European population are what’s called skin-prick test positive for house dust mites, which is a test for sensitivity to allergens to find out if a person is likely to get that allergy.

15 Oct 2013